Clinical Trial Update: First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial assessing safety, tolerability, and preliminary efficacy of an anti-CXCR4 antibody in acute myeloid leukemia and selected B-cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Anti-CXCR4 antibody

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia | Phase 1 | Status: COMPLETED